Verve Therapeutics Inc (VERV) concluded trading on Thursday at a closing price of $4.60, with 5.24 million shares of worth about $24.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -5.15% during that period and on May 29, 2025 the price saw a gain of about 8.49%. Currently the company’s common shares owned by public are about 88.80M shares, out of which, 65.76M shares are available for trading.
Stock saw a price change of 8.75% in past 5 days and over the past one month there was a price change of -15.75%. Year-to-date (YTD), VERV shares are showing a performance of -18.44% which decreased to -12.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.86 but also hit the highest price of $9.31 during that period. The average intraday trading volume for Verve Therapeutics Inc shares is 3.17 million. The stock is currently trading 2.23% above its 20-day simple moving average (SMA20), while that difference is down -1.16% for SMA50 and it goes to -18.68% lower than SMA200.
Verve Therapeutics Inc (NASDAQ: VERV) currently have 88.80M outstanding shares and institutions hold larger chunk of about 73.84% of that.
The stock has a current market capitalization of $410.06M and its 3Y-monthly beta is at 1.67. It has posted earnings per share of -$2.11 in the same period. It has Quick Ratio of 9.84 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VERV, volatility over the week remained 4.64% while standing at 6.03% over the month.
Stock’s fiscal year EPS is expected to drop by -0.95% while it is estimated to decrease by -13.23% in next year. EPS is likely to grow at an annualized rate of 0.40% for next 5-years, compared to annual growth of -42.43% made by the stock over the past 5-years.
Coverage by H.C. Wainwright stated Verve Therapeutics Inc (VERV) stock as a Buy in their note to investors on April 08, 2024, suggesting a price target of $15 for the stock. On April 13, 2023, Canaccord Genuity Initiated their recommendations, while on February 01, 2023, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $21. Stock get a Sell rating from Goldman on December 15, 2022.
